Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea's Fair Trade Commission Looking Into Allegations That MNCs Offered Kickbacks To Block New Generic Entrants

This article was originally published in PharmAsia News

Executive Summary

SEOUL - The South Korean government's fair trade watchdog - the Fair Trade Commission - is investigating reports of "reverse payments" or kickbacks offered to local Korean generic drug makers by multinational pharmaceutical companies to keep generics off the market after patents expire on an original drug

You may also be interested in...

Korea's Health Ministry To Unveil Steeper Price Cuts After Patent Loss; Generics Could Be The Big Loser

SEOUL - Korea's Ministry of Health and Welfare confirmed that it is preparing a new pricing system to further cut prices of both innovative products and generics. The plan could deal a blow to Korea's generic-dependent pharmas by eventually eliminating price differences of generics and off-patent brands under Korea's national health insurance

Brand-Generic "Pay-For-Delay" Settlements Jump 63% In FY 2010

As a proportion of total settlements reported to FTC, however, the ones involving compensation to the generic firm remained the same.

Korean Government Launches Strongest-ever Drive To Root Out Rebates

SEOUL - In the strongest ever all-out government crackdown on rebates between hospital doctors and pharmaceutical companies, the Korean government established a joint task force at a Seoul Prosecution Office that it hopes will add teeth to better enforce anti-rebate laws implemented last November

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts